CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Hiring the Right CRO to Improve Clinical Trial Outcomes

Hiring the Right CRO to Improve...

 Altasciences Receives Accreditation From College Of American Pathologists

Altasciences Receives Accreditation...

Life Science Marketing: Content Distribution for Businesses

Life Science Marketing: Content...

Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

Protypia, Inc.'S Acquisition By...

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Avance Appoints New Business Development Manager APAC

Avance Appoints New Business...

Hiring the Right CRO to Improve Clinical Trial Outcomes

Hiring the Right CRO to Improve...

 Altasciences Receives Accreditation From College Of American Pathologists

Altasciences Receives Accreditation...

Life Science Marketing: Content Distribution for Businesses

Life Science Marketing: Content...

Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

Protypia, Inc.'S Acquisition By...

Making the Most of Contract Research Organization Relationships

Making the Most of Contract Research...

How Cloudbased Lims Helps Cros

How Cloudbased Lims Helps Cros

MMS Holdings Announces New Pro-Bono Support Program

MMS Holdings Announces New Pro-Bono...

Avance Appoints New Business Development Manager APAC

Avance Appoints New Business...

Inotiv Secures MilliporeSigmas BioReliance Genetic Toxicology Assets

Life Sciences Review Life Sciences Review | Tuesday, July 27, 2021
Tweet

Inotiv obtains Genetic Toxicology Assets from MilliporeSigmas BioReliance® portfolio.


FREMONT, CA: Inotiv, Inc., a leading contract research organization specializing in nonclinical and analytical drug discovery and development services, acquires critical genetic toxicology assets from MilliporeSigmas BioReliance® portfolio, including standard operating procedures, stock cultures, historical control data, and client relationships. While Inotiv did not disclose specific financial terms, the transaction is structured as a sales-based royalty arrangement that does not require the Company to make any upfront payments.


Robert Leasure, Jr., President and CEO of Inotiv, comments, "This transaction with MilliporeSigma adds genetic toxicology to our suite of internal capabilities. We now have assembled in-house all of the critical nonclinical services necessary to support our clients goals of advancing to human clinical trials."


MilliporeSigma is ceasing operations in the field of Genetic Toxicology. The agreement with Inotiv is intended to ensure that existing clients receive uninterrupted service. Additionally, Inotiv plans to hire certain MilliporeSigma employees who would have been laid off.


Additionally, Inotiv announces Gopala Krishna, Ph.D., MBA, as Senior Vice President, Genetic Toxicology, to lead the Company's genetic toxicology service offering. Dr. Krishna is a Diplomate of the American Board of Toxicology and a Fellow of the Academy of Toxicological Sciences. He has over three decades of experience in the pharmaceutical industry as a nonclinical leader in drug discovery and development at large and small pharmaceutical companies, including Pfizer, Abbott Laboratories, MGI Pharma, Enzon, and Supernus. 


He has also taught Pharmacology and Toxicology at the University of Michigan's School of Public Health in Ann Arbor, MI. He most recently worked at PAREXEL International as a Principal Consultant - Nonclinical. He is currently the President of the Society of Toxicology's National Capital Area Chapter (NCAC). He has been a contributing senior member of the Environmental Mutagenesis and Genomics (Genetic Toxicology) Society (EMGS) for more than 35 years.


“Evaluation of the potential for novel therapeutics to interact with and alter DNA is a key element of the safety assessment of those drug candidates,” says John E. Sagartz, Chief Strategy Officer of Inotiv. “Inotiv historically has relied on other vendors to provide these key assessments. Im excited to announce the addition of the BioReliance® assets and Dr. Krishna, and we look forward to developing the genetic toxicology business. We believe this is another significant milestone for Inotiv and our clients.”


Dr. Krishna comments, “I am delighted to join Inotiv with the task of expanding the service offering to include genotoxicity capabilities and look forward to leveraging the assets of the BioReliance® portfolio to assist our clients in the development of safe novel therapeutics.”


Inotiv intends to lease space near the current MilliporeSigmas facilities in Rockville, Maryland, to support this new offering.


Weekly Brief

loading
Top 10 Preeminent Cros – 2022
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

Prophesying DNA Sequencing for 2023

Crucial Workflows of Next-Generation Sequencing

An Overview of Next-Generation Sequencing

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/inotiv-secures-milliporesigmas-bioreliance-genetic-toxicology-assets-nwid-465.html